Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(2):345-348. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0094

View: 2312 Download: 53

Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(2):242-251. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0102

View: 4071 Download: 208 Web of Science: 3 Crossref: 4

Takuji Torimura, Hideki Iwamoto

Clin Mol Hepatol. 2021;27(2):236-245. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0204

View: 8113 Download: 373 Web of Science: 40 Crossref: 38

1 |

Viewed By 5338	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5288	MAFLD: How is it different from NAFLD?
Viewed By 5178	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3880	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3832	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search